Literature DB >> 6336292

Pharmacokinetics of tenoxicam in healthy human volunteers.

R C Heintz, T W Guentert, J F Enrico, U C Dubach, R Brandt, F S Jeunet.   

Abstract

Tenoxicam, a thieno-thiazine derivative, belongs to a new chemical class of non-steroidal anti-inflammatory drugs. Single dose kinetics was investigated after intravenous and oral administration to define the disposition and general absorption characteristics of the drug. After intravenous administration of 20 mg tenoxicam to 12 volunteers the time course of the plasma concentrations of unchanged drug followed two-compartment model characteristics. The area under the plasma-concentration time curve in the distribution phase contributed however only 3% or less to the total area. The plasma clearance was low with values ranging from 1.3 to 4.2 ml/min and the volume of distribution Vss was small averaging at 20 to 40% of the total body weight. The median half-life of elimination from the body was found to be 72 hours (range 42 to 100 hours). The disposition was not influenced by sex. Tenoxicam is highly bound to plasma albumin. At pH 7.4 the fraction bound exceeded 99% but was highly dependent on the pH. Plasma protein binding in patients with rheumatic disease was not different from that measured in healthy volunteers. The partitioning of tenoxicam into red blood cells was limited. Erythrocyte concentrations were only 20-30% of the corresponding plasma concentrations. After oral administration of a 20-mg tablet complete and rapid absorption of the drug was observed with maximum plasma levels of 1.7 to 3.6 micrograms/ml reached within 0.5 to 2 hours. Due to the rapid absorption and terminal half-life of the drug its plasma concentration profile after oral administration was very similar to that following intravenous dosing. The pharmacokinetic characteristics of tenoxicam offers a rationale to administer the entire dose in one single portion.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6336292

Source DB:  PubMed          Journal:  Eur J Rheumatol Inflamm        ISSN: 0140-1610


  16 in total

1.  Plasma tenoxicam concentrations after single and multiple oral doses.

Authors:  C Crevoisier; P Heizmann; I Forgo; U C Dubach
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1989 Jan-Mar       Impact factor: 2.441

2.  Lack of effect of tenoxicam on dynamic responses to concurrent oral doses of glucose and glibenclamide.

Authors:  D Hartmann; A Korn; M Komjati; G Heinz; P Haefelfinger; R Defoin; W K Waldhäusl
Journal:  Br J Clin Pharmacol       Date:  1990-08       Impact factor: 4.335

3.  Pharmacokinetics of tenoxicam after oral administration in healthy human subjects of various single doses.

Authors:  R J Francis; J G Allen; D Looi; J S Dixon; H A Bird; V Wright
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1987 Jan-Mar       Impact factor: 2.441

4.  The effect of concurrent aspirin upon plasma concentrations of tenoxicam.

Authors:  R O Day; P D Paull; S Lam; B R Swanson; K M Williams; D N Wade
Journal:  Br J Clin Pharmacol       Date:  1988-10       Impact factor: 4.335

5.  Neither cimetidine nor probenecid affect the pharmacokinetics of tenoxicam in normal volunteers.

Authors:  R O Day; G Geisslinger; P Paull; K M Williams
Journal:  Br J Clin Pharmacol       Date:  1994-01       Impact factor: 4.335

Review 6.  Tenoxicam. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  J P Gonzalez; P A Todd
Journal:  Drugs       Date:  1987-09       Impact factor: 9.546

7.  Single and multiple dose pharmacokinetics of tenoxicam in the elderly.

Authors:  O G Nilsen; R A Walstad; M Eckert; P Heizmann; A Bückert; T Am; I Løge; J Unnvik; E Thue
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

8.  The influence of cholestyramine on the elimination of tenoxicam and piroxicam.

Authors:  T W Guentert; R Defoin; H Mosberg
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 9.  Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents.

Authors:  K T Olkkola; A V Brunetto; M J Mattila
Journal:  Clin Pharmacokinet       Date:  1994-02       Impact factor: 6.447

Review 10.  Tenoxicam and renal function.

Authors:  R C Heintz
Journal:  Drug Saf       Date:  1995-02       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.